NASDAQ:STIMNeuronetics Stock Price, Forecast & News

$1.87

-0.05 (-2.60 %)

(As of 05/29/2020 03:59 PM ET)

Add

Compare

Today's Range

$1.80

Now: $1.87▼

$1.92

50-Day Range

$1.64

MA: $2.16▼

$2.61

52-Week Range

$1.25

Now: $1.87▼

$13.34

Volume3,639 shs

Average Volume134,351 shs

Market Capitalization$35.03 million

P/E RatioN/A

Dividend YieldN/A

Beta1.59

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Neuronetics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.33, Neuronetics has a potential upside of 185.2% from its current price of $1.87.
Amount of Analyst Coverage
Neuronetics has only been the subject of 3 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Neuronetics has received 102 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Neuronetics has received 95 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Neuronetics has received 51.78% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Neuronetics and other stocks. Vote “Outperform” if you believe STIM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STIM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Neuronetics does not currently pay a dividend.
Dividend Growth
Neuronetics does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neuronetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $93,600.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 6.00% of the stock of Neuronetics is held by insiders.
Percentage Held by Institutions
65.20% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Neuronetics are expected to grow in the coming year, from ($1.73) to ($0.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neuronetics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neuronetics is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Neuronetics has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.25 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:STIM

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.neurostar.com

Phone610-640-4202

Debt

Debt-to-Equity Ratio1.03

Current Ratio6.17

Quick Ratio5.94

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$62.66 million

Price / Sales0.56

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.95 per share

Price / Book0.96

Profitability

EPS (Most Recent Fiscal Year)($1.58)

Net Income$-29,040,000.00

Net Margins-55.58%

Return on Equity-68.77%

Return on Assets-33.83%

Miscellaneous

Employees191

Outstanding Shares18,730,000

Market Cap$35.03 million

Next Earnings Date8/4/2020 (Estimated)

OptionableNot Optionable

Receive STIM News and Ratings via Email

Sign-up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.

Neuronetics (NASDAQ:STIM) Frequently Asked Questions

How has Neuronetics' stock been impacted by COVID-19 (Coronavirus)?

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STIM stock has decreased by 9.7% and is now trading at $1.87. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Neuronetics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neuronetics.

When is Neuronetics' next earnings date?

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Neuronetics.

How were Neuronetics' earnings last quarter?

Neuronetics Inc (NASDAQ:STIM) issued its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.13. The business had revenue of $11.48 million for the quarter. Neuronetics had a negative return on equity of 68.77% and a negative net margin of 55.58%. View Neuronetics' earnings history.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics issued an update on its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.8-12 million, compared to the consensus revenue estimate of $13.77 million.

What price target have analysts set for STIM?

4 analysts have issued twelve-month price objectives for Neuronetics' shares. Their forecasts range from $4.00 to $6.00. On average, they anticipate Neuronetics' share price to reach $5.33 in the next twelve months. This suggests a possible upside of 185.2% from the stock's current price. View analysts' price targets for Neuronetics.

Has Neuronetics been receiving favorable news coverage?

News articles about STIM stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Neuronetics earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutNeuronetics.

Are investors shorting Neuronetics?

Neuronetics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 704,900 shares, an increase of 10.3% from the April 30th total of 639,000 shares. Based on an average daily trading volume, of 322,400 shares, the days-to-cover ratio is presently 2.2 days. Approximately 6.6% of the shares of the company are short sold. View Neuronetics' Current Options Chain.

Who are some of Neuronetics' key competitors?

Some companies that are related to Neuronetics include RenovaCare (RCAR), Restoration Robotics (HAIR), BeyondAirInc . (XAIR), Spectral Medical (EDTXF), Venus Concept (VERO), T2 Biosystems (TTOO), PAVmed (PAVM), BRAINSWAY LTD/S (BWAY), SANUWAVE Health (SNWV), AIT Therapeutics (AITB), Pro-Dex (PDEX), Nephros (NEPH), Nephros (NEPHD), Apollo Endosurgery (APEN) and STRATA Skin Sciences (SSKN). View all competitors.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Tonix Pharmaceuticals (TNXP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS), Nokia Oyj (NOK), Novavax (NVAX) and Onconova Therapeutics (ONTX).

Who are Neuronetics' key executives?

Neuronetics' management team includes the following people:

Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)
Mr. Peter L. Donato, CFO, VP & Corp. Sec. (Age 49)
Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)
Ms. Cassie Hallberg, VP of Marketing
Mr. Daniel Guthrie, Chief Commercial Officer & VP (Age 42)

When did Neuronetics IPO?

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.81%), DAFNA Capital Management LLC (2.65%), Quinn Opportunity Partners LLC (2.55%), State Street Corp (1.24%), Two Sigma Investments LP (1.10%) and JPMorgan Chase & Co. (1.03%). Company insiders that own Neuronetics stock include Brian E Farley, Christopher Thatcher, Daniel Guthrie, Gregory Harper, Peter Donato, Stephen Furlong, Stephen M Campe, Wilfred E Jaeger and William Andrew Macan. View institutional ownership trends for Neuronetics.

Which institutional investors are selling Neuronetics stock?

STIM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Alambic Investment Management L.P., Deutsche Bank AG, and Spark Investment Management LLC. View insider buying and selling activity for Neuronetics.

Which institutional investors are buying Neuronetics stock?

STIM stock was acquired by a variety of institutional investors in the last quarter, including Quinn Opportunity Partners LLC, Two Sigma Investments LP, Two Sigma Advisers LP, DAFNA Capital Management LLC, Blair William & Co. IL, JPMorgan Chase & Co., GSA Capital Partners LLP, and BlackRock Inc.. Company insiders that have bought Neuronetics stock in the last two years include Brian E Farley, Daniel Guthrie, Gregory Harper, Stephen Furlong, Stephen M Campe, Wilfred E Jaeger, and William Andrew Macan. View insider buying and selling activity for Neuronetics.

How do I buy shares of Neuronetics?

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $1.87.

How big of a company is Neuronetics?

Neuronetics has a market capitalization of $35.03 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 191 workers across the globe.

What is Neuronetics' official website?

The official website for Neuronetics is www.neurostar.com.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff